Quick Answer
Jazz Pharmaceuticals plc reported Operating Income Loss of -$430.24 million for the year ending 2025.
- Jazz Pharmaceuticals plc showed a decrease of -160.0% in Operating Income Loss from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $10.58 million | Q3 2010: $14.44 million | Q1 2011: $22.60 million | Q2 2011: $33.86 million | Q3 2011: $33.70 million | Q1 2012: $35.74 million | Q2 2012: $39.43 million | Q3 2012: $55.30 million | Q1 2013: $68.19 million | Q2 2013: $77.07 million | Q3 2013: $100.56 million | Q1 2014: -$66.66 million | Q2 2014: $74.29 million | Q3 2014: $58.04 million | Q1 2015: $116.76 million | Q2 2015: $153.30 million | Q3 2015: $131.53 million | Q1 2016: $121.16 million | Q2 2016: $168.74 million | Q3 2016: $136.25 million | Q1 2017: $136.14 million | Q2 2017: $165.04 million | Q3 2017: $86.45 million | Q1 2018: $87.81 million | Q2 2018: $153.20 million | Q3 2018: $188.78 million | Q1 2019: $133.74 million | Q2 2019: $204.28 million | Q3 2019: $133.10 million | Q1 2020: -$189.67 million | Q2 2020: $198.13 million | Q3 2020: $196.21 million | Q1 2021: $162.12 million | Q2 2021: -$69.59 million | Q3 2021: $28.37 million | Q1 2022: $87.55 million | Q2 2022: $85.55 million | Q3 2022: $24.76 million | Q1 2023: $126.06 million | Q2 2023: $157.64 million | Q3 2023: $172.39 million | Q1 2024: $66.21 million | Q2 2024: $199.44 million | Q3 2024: $260.21 million | Q1 2025: -$55.89 million | Q2 2025: -$686.39 million | Q3 2025: $57.51 million.
- Over the full 17 years of available data (2009 to 2025), Jazz Pharmaceuticals plc's Operating Income Loss has declined by 2,800.8%.
- Historical annual values: Fiscal year 2025: -$430.24 million | Fiscal year 2024: $716.63 million | Fiscal year 2023: $578.58 million | Fiscal year 2022: -$65.53 million | Fiscal year 2021: $170.28 million | Fiscal year 2020: $378.07 million | Fiscal year 2019: $532.37 million | Fiscal year 2018: $614.84 million | Fiscal year 2017: $528.84 million | Fiscal year 2016: $591.65 million | Fiscal year 2015: $508.22 million | Fiscal year 2014: $195.59 million | Fiscal year 2013: $340.31 million | Fiscal year 2012: $197.84 million | Fiscal year 2011: $127.83 million | Fiscal year 2010: $57.79 million | Fiscal year 2009: $15.93 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: